The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Crohn’s Disease Drugs Market Research Report 2024
Synopsis
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
The global Crohn’s Disease Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Crohn’s Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Crohn’s Disease Drugs.
Report Scope
The Crohn’s Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Crohn’s Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Crohn’s Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Amgen
Takeda Pharmaceutical
AbbVie
UCB
Ferring
Eli Lilly
Hoffman-La Roche
Bristol-Myers Squibb
Pfizer
Segment by Type
Anti-Inflammatory
Immune system suppressors
Antibiotics
Others
Segment by Application
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Crohn’s Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Crohn’s Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
The global Crohn’s Disease Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Crohn’s Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Crohn’s Disease Drugs.
Report Scope
The Crohn’s Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Crohn’s Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Crohn’s Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Amgen
Takeda Pharmaceutical
AbbVie
UCB
Ferring
Eli Lilly
Hoffman-La Roche
Bristol-Myers Squibb
Pfizer
Segment by Type
Anti-Inflammatory
Immune system suppressors
Antibiotics
Others
Segment by Application
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Crohn’s Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Crohn’s Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Crohn’s Disease Drugs Market Overview
1.1 Product Overview and Scope of Crohn’s Disease Drugs
1.2 Crohn’s Disease Drugs Segment by Type
1.2.1 Global Crohn’s Disease Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Anti-Inflammatory
1.2.3 Immune system suppressors
1.2.4 Antibiotics
1.2.5 Others
1.3 Crohn’s Disease Drugs Segment by Application
1.3.1 Global Crohn’s Disease Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Hospitalshospital Pharmacies
1.3.5 Retail Pharmacies
1.3.6 Online Pharmacies
1.4 Global Crohn’s Disease Drugs Market Size Estimates and Forecasts
1.4.1 Global Crohn’s Disease Drugs Revenue 2019-2030
1.4.2 Global Crohn’s Disease Drugs Sales 2019-2030
1.4.3 Global Crohn’s Disease Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Crohn’s Disease Drugs Market Competition by Manufacturers
2.1 Global Crohn’s Disease Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Crohn’s Disease Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Crohn’s Disease Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Crohn’s Disease Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Crohn’s Disease Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Crohn’s Disease Drugs, Product Type & Application
2.7 Crohn’s Disease Drugs Market Competitive Situation and Trends
2.7.1 Crohn’s Disease Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Crohn’s Disease Drugs Players Market Share by Revenue
2.7.3 Global Crohn’s Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Crohn’s Disease Drugs Retrospective Market Scenario by Region
3.1 Global Crohn’s Disease Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Crohn’s Disease Drugs Global Crohn’s Disease Drugs Sales by Region: 2019-2030
3.2.1 Global Crohn’s Disease Drugs Sales by Region: 2019-2024
3.2.2 Global Crohn’s Disease Drugs Sales by Region: 2025-2030
3.3 Global Crohn’s Disease Drugs Global Crohn’s Disease Drugs Revenue by Region: 2019-2030
3.3.1 Global Crohn’s Disease Drugs Revenue by Region: 2019-2024
3.3.2 Global Crohn’s Disease Drugs Revenue by Region: 2025-2030
3.4 North America Crohn’s Disease Drugs Market Facts & Figures by Country
3.4.1 North America Crohn’s Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Crohn’s Disease Drugs Sales by Country (2019-2030)
3.4.3 North America Crohn’s Disease Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Crohn’s Disease Drugs Market Facts & Figures by Country
3.5.1 Europe Crohn’s Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Crohn’s Disease Drugs Sales by Country (2019-2030)
3.5.3 Europe Crohn’s Disease Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Crohn’s Disease Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Crohn’s Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Crohn’s Disease Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Crohn’s Disease Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Crohn’s Disease Drugs Market Facts & Figures by Country
3.7.1 Latin America Crohn’s Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Crohn’s Disease Drugs Sales by Country (2019-2030)
3.7.3 Latin America Crohn’s Disease Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Crohn’s Disease Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Crohn’s Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Crohn’s Disease Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Crohn’s Disease Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Crohn’s Disease Drugs Sales by Type (2019-2030)
4.1.1 Global Crohn’s Disease Drugs Sales by Type (2019-2024)
4.1.2 Global Crohn’s Disease Drugs Sales by Type (2025-2030)
4.1.3 Global Crohn’s Disease Drugs Sales Market Share by Type (2019-2030)
4.2 Global Crohn’s Disease Drugs Revenue by Type (2019-2030)
4.2.1 Global Crohn’s Disease Drugs Revenue by Type (2019-2024)
4.2.2 Global Crohn’s Disease Drugs Revenue by Type (2025-2030)
4.2.3 Global Crohn’s Disease Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Crohn’s Disease Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Crohn’s Disease Drugs Sales by Application (2019-2030)
5.1.1 Global Crohn’s Disease Drugs Sales by Application (2019-2024)
5.1.2 Global Crohn’s Disease Drugs Sales by Application (2025-2030)
5.1.3 Global Crohn’s Disease Drugs Sales Market Share by Application (2019-2030)
5.2 Global Crohn’s Disease Drugs Revenue by Application (2019-2030)
5.2.1 Global Crohn’s Disease Drugs Revenue by Application (2019-2024)
5.2.2 Global Crohn’s Disease Drugs Revenue by Application (2025-2030)
5.2.3 Global Crohn’s Disease Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Crohn’s Disease Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer AG Crohn’s Disease Drugs Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Crohn’s Disease Drugs Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Takeda Pharmaceutical
6.3.1 Takeda Pharmaceutical Corporation Information
6.3.2 Takeda Pharmaceutical Description and Business Overview
6.3.3 Takeda Pharmaceutical Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takeda Pharmaceutical Crohn’s Disease Drugs Product Portfolio
6.3.5 Takeda Pharmaceutical Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Corporation Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AbbVie Crohn’s Disease Drugs Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 UCB
6.5.1 UCB Corporation Information
6.5.2 UCB Description and Business Overview
6.5.3 UCB Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 UCB Crohn’s Disease Drugs Product Portfolio
6.5.5 UCB Recent Developments/Updates
6.6 Ferring
6.6.1 Ferring Corporation Information
6.6.2 Ferring Description and Business Overview
6.6.3 Ferring Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Ferring Crohn’s Disease Drugs Product Portfolio
6.6.5 Ferring Recent Developments/Updates
6.7 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly Crohn’s Disease Drugs Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Hoffman-La Roche
6.8.1 Hoffman-La Roche Corporation Information
6.8.2 Hoffman-La Roche Description and Business Overview
6.8.3 Hoffman-La Roche Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hoffman-La Roche Crohn’s Disease Drugs Product Portfolio
6.8.5 Hoffman-La Roche Recent Developments/Updates
6.9 Bristol-Myers Squibb
6.9.1 Bristol-Myers Squibb Corporation Information
6.9.2 Bristol-Myers Squibb Description and Business Overview
6.9.3 Bristol-Myers Squibb Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bristol-Myers Squibb Crohn’s Disease Drugs Product Portfolio
6.9.5 Bristol-Myers Squibb Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Corporation Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Crohn’s Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Crohn’s Disease Drugs Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Crohn’s Disease Drugs Industry Chain Analysis
7.2 Crohn’s Disease Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Crohn’s Disease Drugs Production Mode & Process
7.4 Crohn’s Disease Drugs Sales and Marketing
7.4.1 Crohn’s Disease Drugs Sales Channels
7.4.2 Crohn’s Disease Drugs Distributors
7.5 Crohn’s Disease Drugs Customers
8 Crohn’s Disease Drugs Market Dynamics
8.1 Crohn’s Disease Drugs Industry Trends
8.2 Crohn’s Disease Drugs Market Drivers
8.3 Crohn’s Disease Drugs Market Challenges
8.4 Crohn’s Disease Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
